Abstract
We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.
Keywords: Anti-CD20 antibody; B-cell malignancies; SARS-CoV-2 vaccination.
【저자키워드】 SARS-CoV-2 Vaccination., Anti-CD20 antibody, B-cell malignancies, 【초록키워드】 COVID-19, Treatment, Efficacy, COVID-19 vaccine, immune response, vaccination, antibody, BNT162b2, mRNA, immune responses, Patient, Antibody titer, SARS-CoV-2 vaccination, BNT162b2 mRNA COVID-19 vaccine, BNT162b2 mRNA, anti-CD20, B-cell, B-cell malignancies, dose, treatment strategy, B-cells, Treatment strategies, Final, CHOP, investigated, remained, receiving, treated, anticipated, B-cell malignancy, of BNT162b2, 【제목키워드】 mRNA, anti-CD20, dose, Final, increase in, Limited,